Isis Pharmaceuticals, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 147,285 102,049 99,086 108,473
Cost of Revenue - - - -
Gross Profit 147,285 102,049 99,086 108,473
Operating Expenses
Research and Development 184,033 158,458 157,397 145,160
Sales, General and Admin. 14,918 12,515 12,789 11,669
Non-Recurring Items - - - -
Other - - - -
Operating Income (51,666) (68,924) (71,100) (48,356)
Income From Continuing Operations
Add'l Income/Expense Items 4,463 16,895 6,596 7,308
Earnings Before Interest and Tax (47,203) (53,435) (68,058) (47,927)
Interest Expense 19,355 21,152 16,732 13,232
Earnings Before Tax (66,558) (74,587) (84,790) (61,159)
Income Tax (5,914) (9,109) 11 92
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - (1,406) (3,554) (6,879)
Net Income Cont. Operations (60,644) (71,654) (88,355) (68,130)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (60,644) (65,478) (84,801) (61,251)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (60,644) (65,478) (84,801) (61,251)